Sanofi appoints Muzammil Mansuri as Executive Vice President, Strategy & Business Development

Also joins the Executive Committee at the French drugmaker

Sanofi has appointed Muzammil Mansuri as a new member of the Executive Committee, effective from 22 February.

Mansuri joins Sanofi from Gilead Sciences and will take the position of Executive Vice President, Strategy & Business Development.

He will be responsible for all Group strategic planning, business development, strategic intelligence, alliance management and the Sanofi Genzyme Bio Ventures fund.

Mansuri has more than 35 years of experience in the pharmaceutical sector beginning in 1981 with Shell Research where he started as a research scientist. He spent several years with Bristol-Myers Company in various R&D roles with increasing responsibility.

From 2007 to 2010, Mansuri was Chairman and CEO at CGI Pharmaceuticals. Most recently he was Senior Vice President, Research & Development Strategy and Corporate Development at Gilead Sciences.

You may also like

Distribution

Sanofi delivers first medicines from Global Health Unit’s Impact brand portfolio

Sanofi has delivered the first medicines from its Global Health Unit’s not-for-profit Impact brand portfolio to the Republic of Djibouti
Research & Development

Sanofi and Teva's collaboration to deliver inflammatory bowel disease treatment

TEV’574, a novel anti-TL1A therapy, is being developed to treat ulcerative colitis and Crohn’s disease by Sanofi and Teva Pharmaceuticals
Drug Delivery

Sanofi pledges to sell over €10bn in vaccine sales

In less than two years, Sanofi has delivered a competitive mRNA platform with improved potency and thermostability that performs with both viral and bacterial targets
Manufacturing

Sanofi “all in” on artificial intelligence and data science

“Our ambition is to become the first pharma company powered by artificial intelligence at scale, giving our people tools and technologies," Paul Hudson, CEO of Sanofi
Drug Delivery

Sanofi acquires Provention Bio and gains diabetes therapy

Following its acceptance of the tendered shares, Sanofi completed its acquisition of Provention Bio through the merger of a wholly owned subsidiary of Sanofi with and into Provention Bio
Packaging

Haleon and Sanofi to explore sustainable packaging alternatives

The Bottle Collective’s mission is to industrialise a recyclable high-speed, low-cost dry moulded fibre bottle process
Regulatory

Sanofi's ALTUVIIIO approved by the US FDA

"This positive event triggers impairment reversal, positively impacting 2022 IFRS net income"
Subscribe now